Breaking COVID-19 News from the President and CEO of Tulip

May 29, 2020

I’m excited to share this announcement with our Tulip Family of Customers. Black Tie Medical, Inc., the parent company of Tulip Medical Products, has sponsored a first-in-human clinical trial on the Potential Use of Cellular Stromal Vascular Fraction in Post-COVID-19 Pulmonary Injury and Adult Respiratory Distress Syndrome. Dr. Robert W. Alexander, a long-time member of Tulip’s Advisory Board and a pioneer in the field of adipose regenerative therapies, is the Principle Investigator. Read the published paper about this ground-breaking trial in the Journal of Current Medical Research and Opinion (CMRO):

FULL STUDY

In addition to sponsoring the trial and funding patient expenses, Tulip is donating the single-use instrumentation for harvesting the adipose tissue needed to treat these patients. It is enriching to re-direct a portion of our revenues to this exciting and timely project. The trial begins in June. For more information, contact Dr. Robert W. Alexander at rwamd1914@gmail.com.

--

Marcille Pilkington

President and CEO, Tulip Medical Products